HighTower Advisors’s Champions Oncology CSBR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $258K | Buy |
41,901
+6,743
| +19% | +$40.6K | ﹤0.01% | 3334 |
|
|
2026
Q1 | $202K | Hold |
35,158
| – | – | ﹤0.01% | 3474 |
|
|
2025
Q4 | $243K | Hold |
35,158
| – | – | ﹤0.01% | 3214 |
|
|
2025
Q3 | $228K | Hold |
35,158
| – | – | ﹤0.01% | 3261 |
|
|
2025
Q2 | $259K | Hold |
35,158
| – | – | ﹤0.01% | 3057 |
|
|
2025
Q1 | $305K | Sell |
35,158
-4,150
| -11% | -$42K | ﹤0.01% | 2860 |
|
|
2024
Q4 | $337K | Hold |
39,308
| – | – | ﹤0.01% | 2799 |
|
|
2024
Q3 | $191K | Buy |
39,308
+5,000
| +15% | +$23.4K | ﹤0.01% | 3152 |
|
|
2024
Q2 | $178K | Hold |
34,308
| – | – | ﹤0.01% | 3064 |
|
|
2024
Q1 | $168K | Buy |
34,308
+3,070
| +10% | +$18K | ﹤0.01% | 3035 |
|
|
2023
Q4 | $169K | Hold |
31,238
| – | – | ﹤0.01% | 3062 |
|
|
2023
Q3 | $194K | Hold |
31,238
| – | – | ﹤0.01% | 2925 |
|
|
2023
Q2 | $196K | Hold |
31,238
| – | – | ﹤0.01% | 2880 |
|
|
2023
Q1 | $126K | Hold |
31,238
| – | – | ﹤0.01% | 2886 |
|
|
2022
Q4 | $141K | Buy |
31,238
+4,771
| +18% | +$31.2K | ﹤0.01% | 2875 |
|
|
2022
Q3 | $199K | Hold |
26,467
| – | – | ﹤0.01% | 2615 |
|
|
2022
Q2 | $214K | Hold |
26,467
| – | – | ﹤0.01% | 2590 |
|
|
2022
Q1 | $215K | Hold |
26,467
| – | – | ﹤0.01% | 2782 |
|
|
2021
Q4 | $212K | Hold |
26,467
| – | – | ﹤0.01% | 2722 |
|
|
2021
Q3 | $270K | Buy |
26,467
+7,040
| +36% | +$71.6K | ﹤0.01% | 2487 |
|
|
2021
Q2 | $200K | Hold |
19,427
| – | – | ﹤0.01% | 2667 |
|
|
2021
Q1 | $220K | Buy |
19,427
+2,827
| +17% | +$32.8K | ﹤0.01% | 2531 |
|
|
2020
Q4 | $179K | Hold |
16,600
| – | – | ﹤0.01% | 2235 |
|
|
2020
Q3 | $154K | Hold |
16,600
| – | – | ﹤0.01% | 2156 |
|
|
2020
Q2 | $159K | Hold |
16,600
| – | – | ﹤0.01% | 2042 |
|
|
2020
Q1 | $123K | Hold |
16,600
| – | – | ﹤0.01% | 1913 |
|
|
2019
Q4 | $138K | Buy |
+16,600
| New | +$102K | ﹤0.01% | 2047 |
|
Other funds holding CSBR
MFIM
SS
HighTower Advisors's CSBR Position: Q2 2026 in Review
HighTower Advisors increased its Champions Oncology (CSBR) stake by 19% in Q2 2026, buying an estimated $40.6K and bringing the position to 41,901 shares worth $258K. The position accounts for ﹤0.01% of the portfolio, ranked #3334.
HighTower Advisors first reported a position in CSBR in Q4 2019 and has held it in 27 quarters since. The position peaked at $337K in Q4 2024. 8 funds tracked by Wall St. Rank hold CSBR as of Q2 2026.
- HighTower Advisors held 41,901 shares of Champions Oncology worth $258K as of Q2 2026.
- HighTower Advisors bought 6,743 Champions Oncology shares in Q2 2026, an estimated $40.6K.
- Champions Oncology made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3334 holding.
- HighTower Advisors first reported a position in Champions Oncology in Q4 2019 and has held it in 27 quarters since.
- HighTower Advisors's Champions Oncology position peaked at $337K in Q4 2024.
- 8 funds tracked by Wall St. Rank held Champions Oncology as of Q2 2026.
Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.